Complete response letter to the applicant

CurrencyCurrent through May 31, 2023
Citation 21 C.F.R. §314.110
    • This document is available in original version only for vLex customers

      View this document and try vLex for 7 days
    • TRY VLEX
1 cases
  • Gillis v. QRX Pharma Ltd.
    • United States
    • U.S. District Court — Southern District of New York
    • July 6, 2016
    ...("CRL") that describes the deficiencies in the application and, where possible, provides recommendations for achieving approval. See Id. § 314.110.2. QRX's Early Communications with the FDAIn January 2004, QRX met with the FDA in anticipation of filing an Investigational New Drug ("IND") ap......

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT